Peptide conversations have become so dominated by weight loss, recovery and longevity that it is easy to forget how much more ambitious the field can be.
TT-P34 is a useful reminder.
A Parkinson’s Peptide Crosses Into Human Testing
Teitur Trophics announced Phase I results for its first-in-class investigational peptide on September 10, 2026. The findings were also scheduled for presentation at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul on October 5. According to the company, TT-P34 was safe and well tolerated in healthy volunteers and people with early-stage Parkinson’s disease, while pharmacokinetic measurements showed robust exposure in the central nervous system.
The randomized, double-blind, placebo-controlled Phase I program, conducted at the Centre for Human Drug Research in Leiden, the Netherlands, involved 55 healthy volunteers and 12 patients with early-stage Parkinson’s disease. Teitur reported no dose-limiting findings at the doses tested, including when the investigational peptide was administered alongside standard levodopa therapy in the Parkinson’s cohort.
Why Reaching the Central Nervous System Matters
That last part matters. Getting a peptide into the body is one challenge. Getting a therapeutic candidate to meaningfully reach the brain is another.
Teitur reported dose-dependent central nervous system exposure, supported by pharmacokinetic measurements that included cerebrospinal fluid sampling. Those findings provide evidence that TT-P34 can cross into the central nervous system, although detecting a compound in cerebrospinal fluid is not the same as demonstrating adequate delivery to every relevant brain region or proving a therapeutic effect.
Teitur says TT-P34 is designed around a dual mechanism involving mitochondrial and lysosomal function, two cellular systems deeply relevant to neurodegeneration. The peptide is intended to restore neuronal CREB signaling, a pathway involved in cellular survival and the regulation of these systems. That is a compelling biological rationale, but whether the mechanism can protect neurons in people with Parkinson’s disease remains unproven.
The Biomarker Signals Are Encouraging, Not Proof of Disease Modification
In the Parkinson’s cohort, participants received once-weekly subcutaneous treatment for four weeks, followed by additional safety monitoring. Across the 50-day observation period, the company reported coordinated changes in several lysosomal proteins measured in cerebrospinal fluid among many treated participants.
Those are exploratory biomarker observations consistent with activity in the intended biological pathway, not proof that the drug slows Parkinson’s disease. The findings were reported by the company from a small early-stage trial, and larger studies will be needed to establish whether they translate into measurable clinical benefits.
Phase I trials are supposed to answer early questions about safety, tolerability, exposure and dosing — not declare victory over a neurodegenerative disease.
Phase II Will Have to Answer the Harder Questions
Still, this is exactly the kind of peptide story that deserves more attention. TT-P34 has moved through the brutal transition from interesting mechanism to an actual human trial. Teitur says the data support weekly dosing and that it plans a Phase II study in 2027 to explore therapeutic benefit and disease-modifying potential.
That means the next chapter gets harder. Biomarkers have to translate into meaningful clinical outcomes. Safety has to hold up in larger groups. A compelling biological story has to survive contact with a disease that has humbled generations of drug developers.
But “it worked in a mouse” and “it reached the human CNS in a Phase I program” are not the same sentence.
The peptide world should learn to appreciate that difference.
